Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”).
April 21, 2022
· 6 min read